Published in final edited form as:

Synthesis (Stuttg). 2018 March ; 50(5): 1027–1038. doi:10.1055/s-0036-1590946.

Concise Synthesis of Macrocycles by Multicomponent Reactions

Eman M. M. Abdelraheem^{a,b}, Samad Khaksar^{a,c}, Alexander Dömling^a

Alexander Dömling: a.s.s.domling@rug.nl

^aDepartment of Drug Design, University of Groningen, A. Deusinglaan 1, 9713 AV Groningen, The Netherlands ^bChemistry Department, Faculty of Science, Sohag University, Sohag, 82524, Egypt ^cChemistry Department, Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran

Abstract

A short reaction pathway was devised to synthesize a library of artificial 18–27-membered macrocycles. The five-step reaction sequence involves ring opening of a cyclic anhydride with a diamine, esterification, coupling with an amino acid isocyanide, saponification, and, finally, macro-ring closure using an Ugi or, alternatively, a Passerini multicomponent reaction. Three out of the five steps allow for the versatile introduction of linker elements, side chains, and substituents with aromatic, heteroaromatic, and aliphatic character. The versatile pathway is described for 15 different target macrocycles on a mmol scale. Artificial macrocycles have recently become of great interest due to their potential to bind to difficult post-genomic targets.

Graphical Abstract

Keywords

macrocycles; Ugi reaction; Passerini reaction; amino acids; isocyanides

Macrocycles have recently become an emerging class of synthetic targets due to their unusual biological activities.^{1–3} Moreover, their inherent properties allow macrocycles to perform a wide range of functions such as catalysis,^{4,5} gelation,^{6–8} and ion transport.^{9,10} Naturally occurring macrocycles are clinically used as antibiotics, immunosuppressant agents, and anticancer chemotherapeutic agents.^{11,12} In the drug space, macrocycles are

Correspondence to: Alexander Dömling, a.s.s.domling@rug.nl.

Supporting Information

Supporting information for this article is available online at <https://doi.org/10.1055/s-0036-1590946>.

considered to consist a novel class of compounds in between small molecules and biologics, such as monoclonal antibodies. They allow to target post-genomic targets which are difficult to address by small molecules, such as protein–protein interactions (PPIs).¹² While many ways to synthetically access macrocycles have been described, very few syntheses are useful to create libraries of sufficient size and diversity.^{13–15} Therefore, the development of new synthetic methodologies that allow an improved efficient access to this important class of compounds is needed. Among these chemical methodologies are multicomponent reactions (MCRs), in which the products are formed in only one or few synthetic steps.^{16–20} For instance, minimizing the time and effort and access to screening libraries of suitable size, diversity, and physicochemical properties is of major importance in early drug discovery.²¹ We believe that MCRs are amongst the most powerful techniques to synthesize screening libraries, not only of small molecule scaffolds, but also macrocyclic libraries. Several groups are active in the elaboration of synthetic pathways using convergent and fast MCRs, including, for example, the use of universal aziridinealdehyde for peptidic macrocycles and unique S_nAr ring closures to form natural-product-like macrocycles (Figure 1).^{22–24}

In the light of our extended research interest in MCRs^{25,26} and our previous experience in the chemistry of macrocycles, we report herein the use of α -isocyano- ω -carboxylic acids for the synthesis of macrocycles via Ugi and Passerini macrocyclization reactions. The work is an extension of our recent report on macrocycles with the aim to increase the ring sizes and to provide more flexibility in the design of the composition of the macrocycle with regard to small ring fragments, amide groups, and special distribution thereof with respect to the substituents.^{16,20,27,28} The transient conformational space of macrocycles in different solvents of high and low dielectric constants seems to help passive permeation through cell membranes.²⁹ Therefore we believe that synthetic flexibility can ultimately lead to macrocyclic molecules not only with superior binding properties to receptors but also drug-like properties making them suitable to reach intracellular targets.

In the present synthetic strategy, we incorporated recently described synthesis and diversification elements which allow rapid and diverse assembly of the macrocycle linkers.³⁰ Our envisioned synthetic macrocycle pathway consists of the formation of α -amino- ω -carboxylic acids by suitable ring opening of cyclic anhydrides with diamines, amino acid derived isocyanide coupling, and, finally, macrocyclization using an Ugi or a Passerini ring closure (Scheme 1).

We started our study by optimizing the conditions for the first step in our protocol, the synthesis of amino acid esters (Scheme 2), by employing the ring-opening reaction of a cyclic anhydride with a Boc-protected alkyl diamine in $CHCl_3$, followed by deprotection and esterification in a one-pot reaction, by changing the solvent to methanol. The synthesis can be easily performed in parallel by using suitable metal block heaters, thus leading to a manifold of products (SI movie). The reaction was easily scalable and has been performed on a 5 mmol scale.

However, in order to introduce more flexibility in the synthesis of the amino acids on a scale larger than 5 mmol and to avoid the use of halogenated solvents, we performed the ring opening reaction of cyclic anhydride with unprotected alkyl diamines in the aprotic polar

solvent THF (Scheme 2). Under diluted conditions (0.1 M) at room temperature, we slowly dropped the anhydride into the diamine solution and we isolated 10 products **4** in 50–93% yield (Table 1).³⁰ Next followed the esterification step using SOCl₂ (1.2 equiv) in methanol. This route permits us to introduce greater molecular diversity under mild reaction conditions, including substitution and scaffold diversity (Scheme 2).

Next, the potassium salt of an isocyanide ester was coupled to amino acid ester **5** by using EDC (2.0 equiv) and HOBt hydrate (1-Hydroxybenzotriazole hydrate; 1.0 equiv) in CH₂Cl₂ to give α -isocyano- ω -carboxylate **6** in excellent yield (60–90%), followed by a saponification reaction with KOH (1.5 equiv) in ethanol (Table 1, Scheme 3).^{20,28} In the coupling step, the control of solvents and temperature is of high importance. We tested various solvents, such as toluene, DMF, acetonitrile, and CH₂Cl₂ at 0 °C and at room temperature. Only after a reaction in CH₂Cl₂ at 0 °C for 12 hours followed by room temperature for another 12 hours could we isolate the product at good conversion and yield. Gratifyingly, the product could be isolated by filtration followed by a short silica column purification.

Finally, the macrocyclic ring closure by MCRs (U-4CR) with another equivalent of primary amine and an oxo component took place under optimized conditions (Scheme 3). Different solvents were screened, including EtOH, MeOH, toluene, and trifluoroethanol (TFE). The last one proved to be the optimum solvent for the reaction, but we chose MeOH as the cheapest solvent, since we had to work under highly diluted conditions. We found the NH₄Cl additive necessary for freeing the carboxylic acid from the potassium salt of the α -isocyano- ω -carboxylic **7**. Hence, the optimized conditions for the synthesis of macrocycles consisted of stirring of the reagents (1 equiv each) and NH₄Cl (1.5 equiv) in MeOH (0.01 M) as the solvent at room temperature for 48 hours (Scheme 3).

Instead of the Ugi (U-4CR), we also performed a Passerini (P-3CR) macro-ring closure, which led smoothly to depsi-peptide derivatives (Scheme 4). We noted earlier that the classical aprotic nonpolar solvents usually employed in the P-3CR (Et₂O, THF, CH₂Cl₂) did not promote macrocyclization.¹⁶ However, we found that the unusual Passerini reaction solvent water at a 0.01 M dilution leads to product formation. We speculate that the solvent is needed to solubilize the poorly soluble carboxylate in addition to the additive used.

To investigate the substrate scope and limitations we synthesized a total of 15 examples according to Schemes 2 and 3. The last step of the macrocycle synthesis was performed by using several commercially available aliphatic, aromatic, and heterocyclic oxo components as aldehydes and ketones. Also, substituted aromatic amines have been used for the Ugi reaction to afford macrocycle derivatives in moderate yields (20–46%) after purification by column chromatography.

A mechanistic rationalization for the Ugi cyclization reaction is provided in Scheme 5. It is conceivable that the initial event is the condensation of the carbonyl and amino group to form the Schiff base. Next, nucleophilic addition of the terminal carbon of the α -isocyano- ω -carboxylic anion adds to the iminium anion of the Schiff base, followed by an intramolecular nucleophilic addition of the carboxylic acid anion onto the nitrilium ion,

yielding the so-called α -adduct intermediate. This undergoes a Mumm rearrangement with transfer of the acyl group from the oxygen to the nitrogen. All reaction steps are reversible, except the Mumm rearrangement, which drives the whole reaction sequence.

In conclusion, we have introduced a very mild, straightforward, sequential, rapid, and highly diverse macrocycle synthesis pathway via MCRs. The artificial macrocyclic scaffolds were formed by ring closure via Ugi-4CR or Passerini-3CR of α -isocyano- ω -carboxylic acids. The overall sequence used here to introduce different ring sizes and side chain variations by using readily available starting materials comprise of only five synthesis steps. Currently, libraries of such macrocyclic derivatives are screened in our laboratory for biological activity.

NMR spectra were recorded with a Bruker Avance 500 spectrometer (^1H NMR, 500 MHz; ^{13}C NMR, 126 MHz). Chemical shifts for ^{13}C NMR signals are reported in ppm relative to the solvent peak. TLC was performed with Fluka precoated silica gel plates (0.20 mm thick, particle size 25 μm). Flash chromatography was performed with a Teledyne ISCO Combiflash Rf, using RediSep Rf normal-phase silica flash columns (silica gel 60 Å, 230–400 mesh). Reagents were available from commercial suppliers and used without any purification unless otherwise noted. Other reagents were purchased from Sigma Aldrich, ABCR, Acros, and AK Scientific and were used without further purification. Electrospray ionization mass spectra (ESI-MS) were recorded with a Waters Investigator Semi-prep 15 SFC-MS instrument.

α,ω -Amino Carboxylic Acids; General Procedure A

Diamine **1** (5.0 mmol) was dissolved in THF (30 mL), and then a solution of the anhydride (5.0 mmol) in THF (20 mL) was added dropwise over 30 min. The reaction mixture was further stirred for 1 h. The solvents were removed under vacuum. The crude mixture was purified by flash column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9) to afford the product.

Esterification Reaction; General Procedure B

The amino acid (3.0 mmol) was dissolved in MeOH (30 mL) in a flask with a magnetic stirring bar. Thionyl chloride (3.2 mmol) was added dropwise with cooling in an ice bath. The reaction mixture was stirred overnight. The solvent was removed under vacuum, the crude which gave the pure product was dried, and the ester was subjected directly to the next step.

Coupling Reactions; General Procedure C

A suspension of the amino ester derivative (2.0 mmol), the potassium isocyanide derivative (2.2 equiv), and triethylamine (3 equiv) in CH_2Cl_2 (20 mL) was stirred for 10 min at 0 °C. Then HOBt hydrate (1 equiv) and EDC (2 equiv) were added to the mixture, and the reaction mixture was stirred for 12 h at 0 °C, followed by 12 h at rt. The insoluble materials were filtered off and the filtrate was evaporated. The residue was purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Saponification Reactions; General Procedure D

The isocyanide ester (1.0 mmol) was dissolved in EtOH (1 mL), and KOH (1.5 mmol) was added. The reaction mixture was stirred at rt. After consumption of the starting material indicated by TLC, the solvent was removed under vacuum and the potassium salt was subjected directly to the next step.

Macrocyclization via Ugi Reaction; General Procedure E

A mixture of the aldehyde (1.0 mmol) and the amine (1.0 mmol) was stirred at rt for 30 min. Then a solution of the α -isocyano- ω -carboxylic acid salt (1.0 mmol) and ammonium chloride (1.5 mmol) in MeOH (0.01 M, 100 mL) were added to the reaction mixture, which was then stirred further at rt for 48 h. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica gel, CH₂Cl₂–MeOH, 9:1).

Macrocyclization via Passerini Reaction; General Procedure F

A mixture of the α -isocyano- ω -carboxylic acid (1.0 mmol) and ammonium chloride (1.5 mmol) in H₂O (0.01 M, 100 mL) was stirred at rt for 30 min. Then the aldehyde or ketone (1.0 mmol) was added to the mixture, which was further stirred for 72 h. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (silica gel, CH₂Cl₂–MeOH, 9:1).

5-({2-[(2-Aminoethyl)sulfanyl]ethyl}amino)-5-oxopentanoic Acid (4a)

Prepared according to procedure A and purified by column chromatography (silica gel, CH₂Cl₂–MeOH, 1:9).

Yield: 0.761 g (65%); 5 mmol scale; white solid; mp 142–144 °C.

¹H NMR (500 MHz, D₂O): δ = 3.32 (t, J = 6.6 Hz, 2 H), 3.12 (t, J = 6.7 Hz, 2 H), 2.77 (t, J = 6.7 Hz, 2 H), 2.64 (t, J = 6.5 Hz, 2 H), 2.23–2.11 (m, 4 H), 1.81–1.66 (m, 2 H).

¹³C NMR (126 MHz, D₂O): δ = 181.3, 176.4, 38.3, 38.3, 35.7, 35.2, 30.2, 28.1, 21.9.

HRMS (ESI): m/z [M + H]⁺ calcd for C₉H₁₉N₂O₃S: 235.11109; found: 235.11095.

5-[(3-aminopropyl)amino]-3,3-dimethyl-5-oxopentanoic Acid (4b)

Prepared according to procedure A and purified by column chromatography (silica gel, CH₂Cl₂–MeOH, 1:9).

Yield: 0.832 g (77%); 5 mmol scale; white solid; mp 162–164 °C.

¹H NMR (500 MHz, D₂O): δ = 3.03 (s, 2 H), 2.68 (s, 2 H), 2.22 (t, J = 7.5 Hz, 2 H), 2.17–2.12 (m, 2 H), 1.79–1.74 (m, 2 H), 0.91 (s, 6 H).

¹³C NMR (126 MHz, D₂O): δ = 181.5, 177.3, 46.5, 46.2, 45.8, 35.9, 35.0, 34.3, 22.3.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{10}H_{21}N_2O_3$: 217.15467; found: 217.1545.

5-({2-[(2-Aminoethyl)sulfanyl]ethyl}amino)-3,3-dimethyl-5-oxopentanoic Acid (4c)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 0.838 g (64%); 5 mmol scale; yellow oil.

1H NMR (500 MHz, D_2O): δ = 3.43 (t, J = 6.6 Hz, 2 H), 3.14 (t, J = 6.6 Hz, 1 H), 3.09 (t, J = 6.6 Hz, 1 H), 2.83 (dd, J = 15.8, 6.6 Hz, 2 H), 2.75 (t, J = 6.5 Hz, 2 H), 2.28 (s, 2 H), 2.21 (s, 2 H), 1.06 (s, 6 H).

^{13}C NMR (126 MHz, D_2O): δ = 181.2, 175.1, 49.8, 47.7, 38.3, 32.8, 30.3, 29.8, 29.23, 27.5.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{11}H_{23}N_2O_3S$: 263.1424; found: 263.1422.

5-[(3-Aminopropyl)amino]-5-oxopentanoic Acid (4d)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 0.517 g (55%); 5 mmol scale; white solid; mp 150–152 °C.

1H NMR (500 MHz, D_2O): δ = 3.18 (t, J = 6.7 Hz, 2 H), 2.97–2.83 (m, 2 H), 2.16 (t, J = 7.5 Hz, 2 H), 2.09 (t, J = 7.5 Hz, 2 H), 1.83–1.67 (m, 4 H).

^{13}C NMR (126 MHz, D_2O): δ = 182.2, 176.7, 36.9, 36.4, 35.9, 35.3, 26.6, 22.2.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_8H_{17}N_2O_3$: 189.1234; found: 189.1234.

2-({2-[(5-Aminopentyl)amino]-2-oxoethyl}sulfanyl)acetic Acid (4e)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 0.936 g (80%); 5 mmol scale; white solid; mp 140–142 °C.

1H NMR (500 MHz, D_2O): δ = 3.18 (s, 2 H), 3.15 (s, 2 H), 3.13 (t, J = 6.8 Hz, 2 H), 2.89 (t, J = 7.5 Hz, 2 H), 1.62–1.52 (m, 2 H), 1.51–1.42 (m, 2 H), 1.33–1.24 (m, 2 H).

^{13}C NMR (126 MHz, D_2O): δ = 176.7, 172.0, 39.3, 36.9, 35.6, 27.7, 26.3, 22.9.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_9H_{19}N_2O_3S$: 235.1111; found: 235.1111.

2-{2-[(3-Aminopropyl)amino]-2-oxoethoxy}acetic Acid (4f)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 0.570 g (60%); 5 mmol scale; white solid; mp 145–147 °C.

^1H NMR (500 MHz, D_2O): δ = 3.99 (s, 2 H), 3.90 (s, 2 H), 3.27 (t, J = 6.7 Hz, 2 H), 2.93 (t, J = 8.5, 6.8 Hz, 2 H), 1.89–1.77 (m, 2 H).

^{13}C NMR (126 MHz, D_2O): δ = 177.4, 172.9, 70.4, 69.5, 36.9, 35.6, 26.5.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_7\text{H}_{15}\text{N}_2\text{O}_4$: 191.1026; found: 191.1027.

5-[(10-Aminodecyl)amino]-3-methyl-5-oxopentanoic Acid (4g)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 1.39 g (93%); 5 mmol scale; white solid; mp 174–176 °C.

^1H NMR (500 MHz, D_2O): δ = 3.07 (t, J = 6.7 Hz, 2 H), 2.87 (t, J = 7.6 Hz, 2 H), 2.23–2.07 (m, 3 H), 2.04–1.86 (m, 2 H), 1.54 (p, J = 7.3 Hz, 2 H), 1.39 (p, J = 6.7 Hz, 2 H), 1.20 (d, J = 15.2 Hz, 12 H), 0.83 (d, J = 5.6 Hz, 3 H).

^{13}C NMR (126 MHz, D_2O): δ = 181.6, 175.4, 44.6, 43.2, 39.5, 39.2, 29.1, 28.4, 28.2, 28.1, 26.6, 25.8, 25.5, 18.7.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{16}\text{H}_{33}\text{N}_2\text{O}_3$: 301.2486; found: 301.2484.

5-[(4-Aminobutyl)amino]-5-oxopentanoic Acid (4h)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 0.505 g (50%); 5 mmol scale; white solid; mp 159–160 °C.

^1H NMR (500 MHz, D_2O): δ = 3.06 (t, J = 13.1, 6.8 Hz, 2 H), 2.87 (t, J = 7.6 Hz, 2 H), 2.37–2.34 (m, 4 H), 1.60–1.51 (m, 2 H), 1.47–1.36 (m, 2 H), 1.32–1.23 (m, 2 H).

^{13}C NMR (126 MHz, D_2O): δ = 180.3, 175.5, 39.3, 38.8, 32.5, 32.1, 27.7, 26.3, 22.8.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_9\text{H}_{19}\text{N}_2\text{O}_3$: 203.139; found: 203.139.

2-(1-{2-[(5-Aminopentyl)amino]-2-oxoethyl}cyclopentyl)acetic Acid (4i)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 0.945 g (70%); 5 mmol scale; brown oil.

^1H NMR (500 MHz, D_2O): δ = 3.10 (t, J = 6.8 Hz, 2 H), 2.93–2.83 (m, 2 H), 2.25 (s, 2 H), 2.18 (s, 2 H), 1.61–1.50 (m, 6 H), 1.50–1.40 (m, 6 H), 1.36–1.24 (m, 2 H).

^{13}C NMR (126 MHz, D_2O): δ = 180.9, 175.1, 45.8, 44.3, 43.9, 39.3, 38.7, 37.3, 27.8, 26.3, 23.4, 23.1.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{27}\text{N}_2\text{O}_3$: 271.2016; found: 271.2014.

2'-[(2-Aminoethyl)carbamoyl]-[1,1'-biphenyl]-2-carboxylic acid (4i)

Prepared according to procedure A and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 1:9).

Yield: 0.994 g (70%); 5 mmol scale; white solid; mp 169–171 °C.

^1H NMR (500 MHz, D_2O): δ = 7.86 (dd, J = 34.1, 8.3, 1.3 Hz, 2 H), 7.56 (dd, J = 18.4, 7.1, 1.4 Hz, 2 H), 7.45–7.40 (m, 2 H), 7.40–7.37 (m, 2 H), 3.25 (t, J = 6.2 Hz, 2 H), 2.66 (t, J = 6.2 Hz, 2 H).

^{13}C NMR (126 MHz, D_2O): δ = 176.8, 173.0, 136.8, 134.1, 133.3, 131.6, 131.4, 130.0, 129.8, 127.7, 127.4, 125.8, 125.7, 125.0, 42.4, 39.7.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{16}\text{H}_{17}\text{N}_2\text{O}_3$: 285.1234; found: 285.1232.

Methyl 5-({2-[(2-Aminoethyl)sulfanyl]ethyl}amino)-5-oxopentanoate Hydrochloride (5a)

Prepared according to procedure B.

Yield: 0.639 g (75%); 3 mmol scale; white solid; mp 200 °C (decomp).

^1H NMR (500 MHz, MeOD): δ = 3.48 (s, 3 H), 3.23 (t, J = 6.8 Hz, 2 H), 2.98 (t, J = 6.9 Hz, 2 H), 2.67 (t, J = 6.8 Hz, 2 H), 2.53 (t, J = 6.8 Hz, 2 H), 2.24–2.17 (m, 2 H), 2.11 (t, J = 7.5 Hz, 2 H), 1.77–1.67 (m, 2 H).

^{13}C NMR (126 MHz, MeOD): δ = 175.9, 175.2, 49.9, 39.9, 35.8, 33.9, 31.8, 29.6, 22.2.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{10}\text{H}_{21}\text{N}_2\text{O}_3\text{S}$: 249.1267; found: 249.1266.

Methyl 5-[(3-Aminopropyl)amino]-3,3-dimethyl-5-oxopentanoate Hydrochloride (5b)

Prepared according to procedure B.

Yield: 0.662 g (83%); 3 mmol scale; white solid; mp 185 °C (decomp).

^1H NMR (500 MHz, $\text{DMSO}-d_6$): δ = 5.42 (s, 2 H), 3.56 (s, 3 H), 3.13–3.03 (m, 2 H), 2.80–2.69 (m, 2 H), 2.36 (s, 2 H), 2.11 (s, 2 H), 1.74–1.62 (m, 2 H), 1.00 (s, 6 H).

^{13}C NMR (126 MHz, $\text{DMSO}-d_6$): δ = 171.9, 170.8, 51.1, 46.5, 44.9, 36.7, 35.5, 32.5, 27.4, 27.2.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{11}H_{23}N_2O_3$: 231.1703; found: 231.1702.

Methyl 5-({2-[(2-Aminoethyl)sulfanyl]ethyl}amino)-3,3-dimethyl-5-oxopentanoate Hydrochloride (5c)

Prepared according to procedure B.

Yield: 0.655 g (70%); 3 mmol scale; white solid; mp 186 °C (decomp).

1H NMR (500 MHz, MeOD): δ = 3.62 (s, 3 H), 3.18 (t, J = 6.9 Hz, 2 H), 2.99–2.87 (m, 2 H), 2.38 (s, 2 H), 2.23 (s, 2 H), 1.71–1.60 (m, 2 H), 1.60–1.51 (m, 2 H), 1.06 (s, 6 H).

^{13}C NMR (126 MHz, MeOD): δ = 175.1, 174.3, 50.0, 47.9, 46.3, 38.5, 36.9, 34.1, 28.9, 28.3.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{12}H_{25}N_2O_3S$: 277.1580; found: 277.1579.

Methyl 5-[(3-aminopropyl)amino]-5-oxopentanoate Hydrochloride (5d)

Prepared according to procedure B.

Yield: 0.521 g (73%); 3 mmol scale; white solid; mp 200 °C (decomp).

1H NMR (500 MHz, MeOD): δ = 3.61 (s, 3 H), 3.27–3.25 (m, 2 H), 2.89 (t, J = 7.4 Hz, 2 H), 2.37–2.27 (m, 2 H), 2.23 (t, J = 7.5 Hz, 2 H), 1.91–1.82 (m, 2 H), 1.84–1.75 (m, 2 H).

^{13}C NMR (126 MHz, MeOD): δ = 174.9, 173.8, 48.5, 36.8, 35.5, 34.4, 32.5, 27.3, 20.7.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_9H_{19}N_2O_3$: 203.139; found: 203.139.

Methyl 2-({2-[(5-Aminopentyl)amino]-2-oxoethyl}sulfanyl)acetate Hydrochloride (5e)

Prepared according to procedure B.

Yield: 0.749 g (88%); 3 mmol scale; white solid; mp 198 °C (decomp).

1H NMR (500 MHz, DMSO- d_6): δ = 8.12 (t, J = 5.3 Hz, 1 H), 3.63 (s, 3 H), 3.45 (s, 2 H), 3.20 (s, 2 H), 3.06–3.00 (m, 2 H), 2.76–2.70 (m, 2 H), 1.61–1.49 (m, 2 H), 1.39 (m, 2 H), 1.30 (m, 2 H).

^{13}C NMR (126 MHz, DMSO- d_6): δ = 170.68, 168.68, 52.53, 39.05, 38.89, 35.14, 33.59, 28.78, 27.00, 23.60.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{10}H_{21}N_2O_3S$: 249.1267; found: 249.1265.

Methyl 2-{2-[(3-Aminopropyl)amino]-2-oxoethoxy}acetate hydrochloride (5f)

Prepared according to procedure B.

Yield: 0.562 g (78%); 3 mmol scale; white solid; mp 200 °C (decomp).

¹H NMR (500 MHz, MeOD): δ = 4.25 (s, 2 H), 4.08 (s, 2 H), 3.74 (s, 3 H), 3.36 (t, J = 6.6 Hz, 2 H), 2.96 (t, J = 7.4 Hz, 2 H), 1.93–1.79 (m, 2 H).

¹³C NMR (126 MHz, MeOD) δ = 175.2, 171.5, 69.9, 67.7, 50.4, 36.8, 35.1, 27.3.

HRMS (ESI): m/z [M + H]⁺ calcd for C₈H₁₇N₂O₄: 205.1183; found: 205.1183.

Methyl 5-[(10-Aminodecyl)amino]-3-methyl-5-oxopentanoate Hydrochloride (5g)

Prepared according to procedure B.

Yield: 0.945 g (90%); 3 mmol scale; white solid; mp 182 °C (decomp).

¹H NMR (500 MHz, DMSO-*d*₆): δ = 8.10 (s, 2 H), 7.91 (t, J = 5.3 Hz, 1 H), 3.58 (s, 3 H), 3.09–2.94 (m, 2 H), 2.81–2.66 (m, 2 H), 2.34 (dd, J = 14.9 Hz, 5.4 Hz, 1 H), 2.25 (d, J = 6.7 Hz, 1 H), 2.17–2.03 (m, 2 H), 1.97 (dd, J = 13.8 Hz, 7.9 Hz, 1 H), 1.63–1.48 (m, 2 H), 1.44–1.34 (m, 2 H), 1.33–1.19 (m, 12 H), 0.87 (d, J = 6.6 Hz, 3 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 172.9, 171.1, 51.6, 42.5, 40.7, 39.1, 38.8, 29.6, 29.3, 29.2, 29.1, 29.0, 28.0, 27.4, 26.8, 26.3, 19.8.

HRMS (ESI): m/z [M + H]⁺ calcd for C₁₇H₃₅N₂O₃: 315.2642; found: 315.2638.

Methyl 5-[(4-Aminobutyl)amino]-5-oxopentanoate Hydrochloride (5h)

Prepared according to procedure B.

Yield: 0.650 g (86%); 3 mmol scale; white solid; mp 200 °C (decomp).

¹H NMR (500 MHz, MeOD): δ = 3.68 (s, 3 H), 3.35–3.31 (m, 2 H), 3.26 (t, J = 6.8 Hz, 2 H), 3.04–2.93 (m, 2 H), 2.44–2.37 (m, 2 H), 2.31 (t, J = 7.5 Hz, 2 H), 1.98–1.87 (m, 2 H), 1.81–1.67 (m, 1 H), 1.66–1.59 (m, 1 H).

¹³C NMR (126 MHz, DMSO-*d*₆): δ = 173.5, 171.9, 51.7, 38.9, 38.2, 34.8, 33.2, 26.6, 24.9, 21.1.

HRMS (ESI): m/z [M + H]⁺ calcd for C₁₀H₂₁N₂O₃: 217.1547; found: 217.1546.

Methyl 2-(1-{2-[(5-Aminopentyl)amino]-2-oxoethyl}cyclopentyl)acetate Hydrochloride (5i)

Prepared according to procedure B.

Yield: 0.72 g (75%); 3 mmol scale; white solid; mp 200 °C (decomp).

^1H NMR (500 MHz, DMSO): δ = 8.10 (s, 2 H), 7.87 (s, 1 H), 3.54 (s, 3 H), 2.98 (d, J = 5.2 Hz, 2 H), 2.75–2.68 (m, 2 H), 2.49 (s, 2 H), 2.20 (s, 2 H), 1.58–1.51 (m, 8 H), 1.48–1.43 (m, 2 H), 1.39–1.33 (m, 2 H), 1.32–1.24 (m, 2 H).

^{13}C NMR (126 MHz, DMSO): δ = 172.7, 171.1, 51.0, 43.1, 43.4, 43.0, 38.6, 38.0, 37.1, 28.6, 26.6, 23.6, 23.3.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{15}\text{H}_{29}\text{N}_2\text{O}_3$: 285.2173; found: 285.2171.

Methyl 2'-[(2-Aminoethyl)carbamoyl]-[1,1'-biphenyl]-2-carboxylate Hydrochloride (5j)

Prepared according to procedure B.

Yield: 0.601 g (60%); 3 mmol scale; white solid; mp 187 °C (decomp).

^1H NMR (500 MHz, MeOD): δ = 7.84 (d, J = 7.8 Hz, 1 H), 7.59 (d, J = 7.6 Hz, 2 H), 7.57–7.49 (m, 1 H), 7.48–7.42 (m, 2 H), 7.31 (d, J = 7.6 Hz, 1 H), 7.23 (d, J = 7.6 Hz, 1 H), 3.63 (s, 3 H), 3.33 (dd, J = 8.4 Hz, 4.8 Hz, 2 H), 2.86–2.79 (m, 2 H).

^{13}C NMR (126 MHz, MeOD): δ = 170.0, 167.4, 139.7, 138.4, 133.3, 129.8, 129.2, 129.0, 128.3, 128.1, 127.7, 125.9, 125.7, 125.3, 49.9, 37.6, 35.5.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{17}\text{H}_{19}\text{N}_2\text{O}_3$: 299.1390; found: 299.1388.

Methyl 5-[(2-[(2-(6-Isocyanohexanamido)ethyl)sulfanyl]ethyl)amino]-5-oxopentanoate (6a)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.296 g (40%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 6.80 (s, 1 H), 6.66 (s, 1 H), 3.70–3.58 (m, 5 H), 3.45–3.40 (m, 4 H), 2.69–2.64 (m, 4 H), 2.39–2.34 (m, 2 H), 2.32–2.18 (m, 4 H), 1.96–1.92 (m, 2 H), 1.76–1.59 (m, 4 H), 1.54–1.41 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.0, 170.3, 169.6, 155.7, 71.0, 68.6, 52.1, 41.4, 36.3, 35.8, 35.7, 29.5, 28.8, 25.9, 24.7.

HRMS (ESI): m/z [$\text{M} + 2\text{H}$] $^+$ calcd for $\text{C}_{17}\text{H}_{31}\text{N}_3\text{O}_4\text{S}$: 373.28495; found: 373.28468.

Methyl 5-[(3-(6-Isocyanohexanamido)propyl)amino]-3,3-dimethyl-5-oxopentanoate (6b)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.445 g (63%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 6.91 (s, 1 H), 6.73 (s, 1 H), 3.67 (s, 3 H), 3.38 (ddd, J = 6.5 Hz, 4.9 Hz, 1.7, 2 H), 3.25 (td, J = 12.4 Hz, 6.2 Hz, 4 H), 2.36 (s, 2 H), 2.25 (s, 2 H), 2.21 (t, J = 7.5 Hz, 2 H), 1.74–1.57 (m, 6 H), 1.52–1.40 (m, 2 H), 1.06 (d, J = 19.5 Hz, 6 H).

^{13}C NMR (126 MHz, CDCl_3) δ = 173.3, 172.9, 172.0, 51.5, 47.3, 44.9, 41.4, 36.3, 35.8, 35.7, 33.4, 29.8, 28.8, 28.5, 25.9, 24.7.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{18}\text{H}_{32}\text{N}_2\text{O}_4$: 354.2387; found: 354.2385.

Methyl 5-[(2-[(2-(6-Isocyanohehexanamido)ethyl)sulfanyl]ethyl)amino]-3,3-dimethyl-5-oxopentanoate (6c)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.622 g (78%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 3.69 (s, 3 H), 3.67 (d, J = 6.0 Hz, 1 H), 3.61–3.58 (m, 4 H), 3.57–3.53 (m, 4 H), 3.52 (d, J = 7.0 Hz, 1 H), 3.45 (q, J = 5.1 Hz, 4 H), 2.48 (t, J = 5.9 Hz, 2 H), 2.38 (s, 2 H), 2.27 (s, 2 H), 1.20 (t, J = 7.0 Hz, 2 H), 1.09 (s, 6 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.3, 173.0, 172.0, 155.7, 51.5, 47.3, 44.9, 41.4, 36.3, 35.8, 35.7, 33.4, 29.8, 28.8, 28.5, 25.9, 24.7.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{19}\text{H}_{34}\text{N}_3\text{O}_4\text{S}$: 400.22645; found: 400.22596.

Methyl 5-[(3-(6-Isocyanohehexanamido)propyl)amino]–5-oxopentanoate (6d)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.357 g (55%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3) δ = 6.45 (s, 1 H), 6.41 (s, 1 H), 3.68 (d, J = 2.0 Hz, 3 H), 3.45–3.37 (m, 2 H), 3.33–3.22 (m, 4 H), 2.39 (t, J = 7.2 Hz, 2 H), 2.31–2.20 (m, 4 H), 2.03–1.92 (m, 2 H), 1.77–1.66 (m, 4 H), 1.66–1.59 (m, 2 H), 1.55–1.44 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3) δ = 173.8, 173.6, 173.1, 161.7, 51.6, 41.6, 37.8, 36.3, 36.0, 35.5, 33.2, 29.6, 29.0, 26.3, 25.2, 21.0.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{16}\text{H}_{27}\text{N}_3\text{O}_4$: 326.20743; found: 326.20743.

Methyl 2-[(2-[[5-(4-Isocyanobutanamido)pentyl]amino]-2-oxoethyl)sulfanyl]acetate (6e)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.439 g (64%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 6.99 (s, 1 H), 6.31 (s, 1 H), 3.72 (s, 3 H), 3.52–3.43 (m, 2 H), 3.32 (s, 2 H), 3.30 (s, 2 H), 3.28–3.18 (m, 4 H), 2.35 (t, J = 7.1 Hz, 2 H), 2.03–1.94 (m, 2 H), 1.57–1.48 (m, 4 H), 1.38–1.30 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 171.3, 170.5, 168.4, 156.0, 52.7, 41.1, 39.4, 39.2, 36.3, 34.2, 32.2, 29.0, 28.8, 24.7, 23.9.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{15}\text{H}_{26}\text{N}_3\text{O}_4\text{S}$: 344.1639; found: 344.1636.

Methyl 2-(2-[[3-(6-Isocyanohexanamido)propyl]amino]-2-oxoethoxy)acetate (6f)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.464 g (71%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 7.34–7.24 (m, 1 H), 6.70 (t, J = 5.8 Hz, 1 H), 4.17 (s, 2 H), 4.05 (s, 2 H), 3.74 (s, 3 H), 3.39–3.34 (m, 2 H), 3.35–3.30 (m, 2 H), 3.26–3.21 (m, 2 H), 2.19 (t, J = 7.5 Hz, 2 H), 1.74–1.61 (m, 6 H), 1.47–1.38 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3) δ = 173.1, 170.3, 169.8, 155.7, 71.1, 68.6, 52.1, 36.3, 35.8, 35.7, 29.5, 28.8, 25.9, 24.7.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{15}\text{H}_{25}\text{N}_3\text{O}_5$: 328.18670; found: 328.18642.

Methyl 5-[[10-(6-Isocyanohexanamido)decyl]amino]-3-methyl-5-oxopentanoate (6g)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.541 g (62%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 5.98 (s, 1 H), 5.92 (s, 1 H), 3.65 (s, 3 H), 3.46–3.30 (m, 2 H), 3.27–3.13 (m, 4 H), 2.50–2.32 (m, 2 H), 2.29–2.12 (m, 4 H), 2.06 (dd, J = 13.8 Hz, 7.3 Hz, 1 H), 1.75–1.58 (m, 4 H), 1.54–1.38 (m, 6 H), 1.35–1.19 (m, 12 H), 0.99 (d, J = 6.6 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.1, 172.5, 171.6, 155.7, 51.5, 43.1, 41.4, 40.5, 39.5, 39.4, 39.3, 36.3, 29.6, 29.3, 29.1, 28.8, 28.2, 26.8, 26.0, 24.8, 19.9.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{44}\text{N}_2\text{O}_4$: 438.3326; found: 438.3325.

Methyl 5- $\{[4-(3\text{-isocyanopropanamido})\text{butyl}]\text{amino}\}$ -5-oxopentanoate (6h)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.333 g (56%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 5.95 (m, 1 H), 3.67 (s, 3 H), 3.35–3.23 (m, 4 H), 2.58 (t, J = 6.6 Hz, 1 H), 2.50–2.43 (m, 2 H), 2.43–2.35 (m, 2 H), 2.29–2.20 (m, 2 H), 2.02–1.91 (m, 2 H), 1.59–1.50 (m, 4 H), 1.29–1.20 (m, 1 H), 0.90–0.83 (m, 1 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.3, 172.6, 172.3, 161.5, 51.7, 39.1, 39.0, 38.8, 37.1, 35.5, 33.1, 27.1, 26.6, 20.9.

HRMS (ESI): m/z $[\text{M} + 2\text{H}]^+$ calcd for $\text{C}_{14}\text{H}_{25}\text{N}_3\text{O}_4$: 299.18599; found: 299.18593.

Methyl 2-[1-(2- $\{[5-(6\text{-isocyanohexanamido})\text{pentyl}]\text{amino}\}$ -2-oxoethyl)cyclopentyl]acetate (6i)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.407 g (50%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 5.85 (s, 1 H), 3.69 (s, 3 H), 3.46–3.33 (m, 2 H), 3.28–3.15 (m, 4 H), 2.43 (s, 2 H), 2.30 (s, 2 H), 2.19 (t, J = 7.4 Hz, 1 H), 1.71–1.64 (m, 8 H), 1.54–1.47 (m, 12 H), 1.39–1.31 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.8, 172.6, 171.7, 155.7, 51.6, 44.4, 42.0, 41.4, 39.2, 38.8, 38.2, 36.2, 29.3, 28.9, 28.8, 27.4, 26.0, 24.7, 24.0, 23.8.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{22}\text{H}_{38}\text{N}_3\text{O}_4$: 408.28568; found: 408.28513.

Methyl 2'- $\{[2-(6\text{-isocyanohexanamido})\text{ethyl}]\text{carbamoyl}\}$ - $[1,1'\text{-biphenyl}]\text{-2-carboxylate}$ (6j)

Prepared according to procedure C and purified by manual column chromatography (silica gel, PE–EtOAc, 2:8).

Yield: 0.370 g (44%); 2 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 7.84 (dd, J = 7.6 Hz, 1.5 Hz, 1 H), 7.62–7.58 (m, 1 H), 7.53–7.43 (m, 2 H), 7.40 (dd, J = 5.7 Hz, 3.3 Hz, 2 H), 7.24 (dd, J = 7.4 Hz, 1.3 Hz, 1 H),

7.13–7.01 (m, 1 H), 6.78 (t, $J = 6.0$ Hz, 1 H), 6.24 (t, $J = 5.0$ Hz, 1 H), 3.71 (s, 3 H), 3.41–3.32 (m, 2 H), 3.33–3.23 (m, 1 H), 3.15–3.04 (m, 1 H), 3.04–2.93 (m, 1 H), 2.90–2.80 (m, 1 H), 2.07 (t, $J = 7.5$ Hz, 2 H), 1.70–1.54 (m, 4 H), 1.48–1.35 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3): $\delta = 172.8, 170.5, 169.1, 155.8, 141.5, 138.9, 135.6, 131.6, 130.7, 130.5, 129.7, 129.3, 129.2, 127.9, 127.9, 127.6, 52.6, 41.4, 40.1, 39.3, 36.0, 28.8, 25.9, 24.6$.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{28}\text{N}_3\text{O}_4$: 422.2074; found: 422.2071.

10-Benzyl-11-isobutyl-1-thia-4,10,13,20-tetraazacyclodocosane-5,9,12,19-tetraone (8a)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.244 g (46%); 1 mmol scale; colorless oil.

^1H NMR (500 MHz, CDCl_3): $\delta = 7.37$ – 7.31 (m, 2 H), 7.30 – 7.28 (m, 1 H), 7.17 (d, $J = 7.6$ Hz, 2 H), 7.13 (t, $J = 5.3$ Hz, 1 H), 6.73 – 6.64 (m, 1 H), 6.34 (t, $J = 5.9$ Hz, 1 H), 5.04 – 4.95 (m, 1 H), 4.59 (d, $J = 4.1$ Hz, 2 H), 3.57 – 3.38 (m, 6 H), 3.01 – 2.90 (m, 1 H), 2.75 – 2.71 (m, 2 H), 2.63 (t, $J = 6.0$ Hz, 2 H), 2.50 (m, 1 H), 2.35 – 2.24 (m, 3 H), 2.24 – 2.13 (m, 1 H), 2.06 – 1.99 (m, 1 H), 1.98 – 1.84 (m, 2 H), 1.70 – 1.63 (m, 2 H), 1.50 (m, 3 H), 1.37 – 1.27 (m, 3 H), 0.84 (d, $J = 6.6$ Hz, 3 H), 0.79 (d, $J = 6.6$ Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): $\delta = 175.2, 173.9, 173.5, 171.0, 137.7, 129.0, 127.6, 126.2, 59.8, 56.5, 48.8, 39.0, 38.9, 36.8, 36.6, 35.5, 33.4, 33.2, 32.8, 29.0, 26.6, 25.7, 25.4, 23.1, 22.4, 21.6$.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{45}\text{N}_4\text{O}_4\text{S}$: 533.3156; found: 533.3155.

4-(4-Chlorobenzyl)-3-isobutyl-7,7-dimethyl-1,4,10,14-tetraazacycloicosane-2,5,9,15-tetraone (8b)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.120 g (22%); 1 mmol scale; colorless oil; rotamers are observed and the major was used.

^1H NMR (500 MHz, CDCl_3): $\delta = 7.61$ (t, $J = 5.6$ Hz, 1 H), 7.25 (d, $J = 8.5$ Hz, 2 H), 7.09 (d, $J = 8.4$ Hz, 2 H), 6.99 (t, $J = 5.3$ Hz, 1 H), 5.99 (t, $J = 6.0$ Hz, 1 H), 5.26 – 5.17 (m, 1 H), 4.62 (d, $J = 17.8$ Hz, 1 H), 4.51 (d, $J = 17.8$ Hz, 1 H), 3.44 – 3.34 (m, 1 H), 3.30 – 3.24 (m, 2 H), 3.18 – 3.09 (m, 2 H), 3.04 – 2.97 (m, 1 H), 2.77 (d, $J = 12.7$ Hz, 1 H), 2.46 (d, $J = 15.1$ Hz, 1 H), 2.24 – 2.19 (m, 3 H), 1.94 (d, $J = 12.7$ Hz, 1 H), 1.82 – 1.76 (m, 1 H), 1.69 – 1.61 (m, 4 H), 1.53 – 1.47 (m, 2 H), 1.46 – 1.41 (m, 2 H), 1.39 – 1.33 (m, 2 H), 1.03 (s, 3 H), 0.96 (s, 3 H), 0.88 (dd, $J = 6.2$ Hz, 2.3 Hz, 6 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 174.4, 173.4, 172.4, 170.4, 136.1, 133.2, 128.9, 127.7, 59.2, 48.0, 47.1, 42.0, 38.6, 37.5, 36.4, 36.2, 35.6, 34.4, 30.0, 29.6, 29.2, 27.7, 25.6, 25.2, 24.0, 23.0, 22.5.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{46}\text{N}_4\text{O}_4\text{Cl}$: 549.3202; found: 549.3206.

10-Benzyl-11-isopropyl-7,7-dimethyl-1-thia-4,10,13,20-tetraazacyclodocosane-5,9,12,19-tetraone (8c)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.191 g (35%); 1 mmol scale; colorless oil.

^1H NMR (500 MHz, CDCl_3): δ = 7.96 (s, 1 H), 7.32 (t, J = 7.4 Hz, 2 H), 7.27 (d, J = 7.2 Hz, 1 H), 7.10 (d, J = 7.4 Hz, 2 H), 6.69 (s, 1 H), 6.34 (t, J = 5.5 Hz, 1 H), 4.76 (d, J = 17.4 Hz, 1 H), 4.69 (d, J = 17.4 Hz, 1 H), 4.59 (s, 1 H), 3.68–3.58 (m, 1 H), 3.56–3.43 (m, 2 H), 3.43–3.30 (m, 2 H), 3.20–3.07 (m, 2 H), 2.80–2.66 (m, 5 H), 2.49–2.42 (m, 1 H), 2.39 (s, 2 H), 2.30–2.24 (m, 2 H), 1.77–1.68 (m, 2 H), 1.50–1.44 (m, 2 H), 1.43–1.37 (m, 2 H), 1.08 (s, 3 H), 1.04 (s, 3 H), 0.98 (d, J = 6.4 Hz, 3 H), 0.89 (d, J = 6.7 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 175.2, 173.5, 171.9, 169.6, 137.2, 128.7, 127.4, 126.0, 62.2, 49.3, 47.4, 42.5, 38.9, 38.8, 38.2, 36.2, 34.7, 31.7, 31.4, 29.5, 29.1, 28.3, 26.9, 26.3, 24.7, 19.9, 19.3.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{29}\text{H}_{47}\text{N}_4\text{O}_4\text{S}$: 547.3313; found: 547.3315.

4-Benzyl-3-[2-(methylsulfonyl)ethyl]-1,4,10,14-tetraazacycloicosane-2,5,9,15-tetraone (8d)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield 0.176 g (35%); 1 mmol scale; colorless oil; rotamers are observed (1:1).

^1H NMR (500 MHz, CDCl_3): δ = 7.35 (t, J = 7.5 Hz, 3 H), 7.27 (t, J = 4.4 Hz, 3 H), 7.20 (d, J = 7.5 Hz, 2 H), 7.04 (t, J = 5.8 Hz, 1 H), 6.76 (t, J = 6.3 Hz, 1 H), 6.57–6.45 (m, 2 H), 5.10 (t, J = 7.2 Hz, 1 H), 4.86 (d, J = 15.3 Hz, 1 H), 4.70 (d, J = 17.4 Hz, 2 H), 4.49 (d, J = 17.5 Hz, 1 H), 4.34 (d, J = 15.3 Hz, 1 H), 4.20–4.09 (m, 1 H), 3.45–3.17 (m, 11 H), 3.20–3.07 (m, 2 H), 3.07–2.96 (m, 1 H), 2.93–2.84 (m, 1 H), 2.57–2.48 (m, 2 H), 2.48–2.30 (m, 9 H), 2.29–2.20 (m, 6 H), 2.19–2.06 (m, 3 H), 2.03 (s, 3 H), 1.99 (s, 3 H), 1.98–1.92 (m, 2 H), 1.86–1.74 (m, 2 H), 1.72–1.60 (m, 8 H), 1.58–1.47 (m, 4 H), 1.47–1.32 (m, 4 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 174.5, 174.3, 173.9, 173.6, 173.4, 173.3, 170.2, 169.4, 138.8, 137.2, 128.9, 128.3, 127.7, 127.5, 126.9, 126.3, 59.3, 57.2, 49.3, 46.9, 39.2, 39.0, 36.4, 36.3, 35.9, 35.5, 35.1, 33.5, 32.5, 32.4, 31.1, 30.5, 29.7, 29.4, 29.3, 28.5, 28.3, 28.1, 26.1, 25.9, 24.8, 24.7, 23.3, 21.6, 21.3, 21.0, 15.2, 14.2.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{26}H_{41}N_4O_4S$: 505.2843; found: 505.2847.

5-[2-(Methylsulfanyl)ethyl]-4-phenethyl-1-thia-4,7,12,18-tetraazacycloicosane-3,6,11,19-tetraone (8e)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.268 g (50%); 1 mmol scale; yellow oil; a mixture of rotamers is observed.

1H NMR (500 MHz, $CDCl_3$): δ = 8.19 (s, 1 H), 7.29 (q, J = 6.8, 6.3 Hz, 3 H), 7.22 (d, J = 7.5 Hz, 2 H), 7.20–7.15 (m, 5 H), 7.14 (s, 1 H), 6.87 (s, 1 H), 6.60 (s, 1 H), 6.16 (t, J = 5.6 Hz, 1 H), 4.63 (t, J = 7.0 Hz, 1 H), 4.60–4.55 (m, 1 H), 3.83 (d, J = 14.2 Hz, 1 H), 3.68–3.60 (m, 1 H), 3.59–3.49 (m, 3 H), 3.48–3.33 (m, 5 H), 3.33–3.22 (m, 7 H), 3.23–3.08 (m, 6 H), 3.08–2.97 (m, 2 H), 2.98–2.82 (m, 2 H), 2.80–2.69 (m, 1 H), 2.61–2.40 (m, 6 H), 2.40–2.26 (m, 1 H), 2.26–2.14 (m, 5 H), 2.08 (s, 4 H), 2.06 (s, 2 H), 1.90–1.68 (m, 5 H), 1.57–1.44 (m, 7 H), 1.41–1.32 (m, 3 H), 1.30–1.18 (m, 1 H).

^{13}C NMR (126 MHz, $CDCl_3$): δ = 173.4, 173.2, 170.3, 170.2, 170.1, 169.7, 169.1, 168.7, 139.1, 137.6, 128.9, 128.8, 128.7, 128.6, 127.1, 126.5, 59.7, 59.0, 49.9, 47.0, 39.2, 39.1, 38.9, 38.8, 38.5, 38.0, 37.3, 35.9, 35.1, 35.0, 34.4, 33.8, 33.7, 33.2, 31.0, 30.5, 29.1, 28.4, 28.1, 27.9, 26.8, 26.0, 24.7, 23.3, 22.6, 15.4, 15.3.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{26}H_{41}N_4O_4S_2$: 537.2564; found: 537.2565.

4-(4-Chlorobenzyl)-5-isobutyl-1-oxa-4,7,14,18-tetraazacycloicosane-3,6,13,19-tetraone (8f)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.209 g (40%); 1 mmol scale; colorless oil; rotamers are observed and the major was used.

1H NMR (500 MHz, $CDCl_3$): δ = 8.43 (s, 1 H), 7.30 (d, J = 8.4 Hz, 1 H), 7.24 (d, J = 8.4 Hz, 1 H), 7.21 (d, J = 8.4 Hz, 1 H), 7.10 (d, J = 8.3 Hz, 1 H), 6.99 (s, J = 5.0 Hz, 1 H), 5.89 (t, J = 5.8 Hz, 1 H), 5.08 (t, J = 7.3 Hz, 1 H), 4.58–4.51 (m, 2 H), 4.19 (d, J = 14.9 Hz, 1 H), 4.16–4.09 (m, 2 H), 3.84 (d, J = 15.6 Hz, 1 H), 3.62–3.52 (m, 1 H), 3.46–3.38 (m, 1 H), 3.36–3.29 (m, 2 H), 3.27–3.14 (m, 2 H), 2.28–2.18 (m, 2 H), 1.88–1.80 (m, 1 H), 1.76–1.68 (m, 2 H), 1.68–1.60 (m, 2 H), 1.54–1.44 (m, 2 H), 1.44–1.36 (m, 4 H), 0.89 (t, J = 5.7 Hz, 6 H).

^{13}C NMR (126 MHz, $CDCl_3$): δ = 173.6, 171.1, 170.1, 169.7, 135.4, 133.5, 129.1, 127.3, 72.3, 70.5, 56.4, 46.8, 38.0, 37.5, 36.7, 35.7, 35.3, 29.4, 27.6, 25.3, 25.2, 23.4, 22.9, 22.4.

HRMS (ESI): m/z $[M + H]^+$ calcd for $C_{26}H_{40}N_4O_5Cl$: 523.2682; found: 523.2683.

4-Benzyl-3-isopropyl-1,4,10,14-tetraazacycloicosane-2,5,9,15-tetraone (8g)

Prepared according to procedure E and purified by column chromatography (silica gel, CH₂Cl₂–MeOH, 9:1).

Yield: 0.169 g (36%); 1 mmol scale; brown oil; rotamers are observed and the major was used.

¹H NMR (500 MHz, CDCl₃): δ = 7.33 (t, *J* = 7.4 Hz, 1 H), 7.25 (t, *J* = 8.5 Hz, 2 H), 7.17 (d, *J* = 7.4 Hz, 2 H), 7.10 (s, 1 H), 6.83 (s, 1 H), 6.27 (s, 1 H), 4.69 (d, *J* = 17.1 Hz, 1 H), 4.58 (d, *J* = 17.1 Hz, 1 H), 4.29 (s, 1 H), 3.56–3.45 (m, 1 H), 3.44–3.11 (m, 4 H), 3.10–2.93 (m, 1 H), 2.76 (s, 1 H), 2.55–2.46 (m, 1 H), 2.46–2.35 (m, 2 H), 2.34–2.21 (m, 3 H), 2.20–2.02 (m, 2 H), 1.94–1.82 (m, 2 H), 1.74–1.46 (m, 4 H), 1.45–1.30 (m, 2 H), 0.96 (d, *J* = 6.4 Hz, 3 H), 0.81 (dd, *J* = 13.1 Hz, 6.7 Hz, 3 H).

¹³C NMR (126 MHz, CDCl₃): δ = 175.2, 174.4, 173.9, 170.4, 137.1, 128.7, 127.5, 126.6, 67.0, 50.3, 40.7, 40.0, 39.7, 38.7, 36.1, 35.6, 32.9, 28.4, 26.8, 26.3, 24.4, 21.8, 19.9, 19.3.

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₆H₄₁N₄O₄: 473.3970; found: 473.2965.

4-(4-Chlorobenzyl)-3-isobutyl-1,4,10,14-tetraazacycloicosane-2,5,9,15-tetraone (8h)

Prepared according to procedure E and purified by column chromatography (silica gel, CH₂Cl₂–MeOH, 9:1).

Yield: 0.208 g (40%); 1 mmol scale; colorless oil; rotamers are observed and the major was used.

¹H NMR (500 MHz, CDCl₃): δ = 7.35–7.30 (m, 1 H), 7.29 (d, *J* = 2.8 Hz, 1 H), 7.22 (d, *J* = 2.0 Hz, 2 H), 7.13 (d, *J* = 8.2 Hz, 1 H), 6.33–6.20 (m, 1 H), 4.81–4.60 (m, 1 H), 4.56–4.42 (m, 1 H), 3.50–3.37 (m, 2 H), 3.35–3.25 (m, 2 H), 3.26–3.11 (m, 2 H), 3.12–3.04 (m, 1 H), 2.47–2.35 (m, 2 H), 2.34–2.23 (m, 3 H), 2.22–2.15 (m, 2 H), 2.10–2.00 (m, 1 H), 2.01–1.92 (m, 1 H), 1.93–1.82 (m, 1 H), 1.71–1.59 (m, 4 H), 1.56–1.49 (m, 2 H), 1.47–1.33 (m, 4 H), 0.90 (d, *J* = 6.5 Hz, 3 H), 0.86 (d, *J* = 6.6 Hz, 2 H), 0.79 (d, *J* = 6.6 Hz, 1 H).

¹³C NMR (126 MHz, CDCl₃): δ = 174.5, 173.8, 173.3, 170.7, 137.7, 133.0, 128.8, 128.1, 64.1, 59.0, 48.0, 39.5, 39.0, 36.2, 35.8, 35.4, 32.4, 29.5, 28.5, 26.0, 25.2, 24.6, 22.7, 22.5, 21.2.

HRMS (ESI): *m/z* [M + H]⁺ calcd for C₂₇H₄₂N₄O₄Cl: 521.2889; found: 521.2891.

9-Methyl-6-phenethyl-6,12,23,30-tetraazaspiro[4.26]hentriacontane-7,11,24,31-tetraone (8i)

Prepared according to procedure E and purified by column chromatography (silica gel, CH₂Cl₂–MeOH, 9:1).

Yield: 0.292 g (48%); 1 mmol scale; colorless oil.

^1H NMR (500 MHz, CDCl_3): δ = 7.35 (t, J = 7.4 Hz, 2 H), 7.27 (d, J = 7.4 Hz, 1 H), 7.22 (d, J = 7.3 Hz, 2 H), 6.69 (s, 1 H), 6.34 (s, 1 H), 5.95 (s, 1 H), 3.68–3.56 (m, 2 H), 3.32–3.18 (m, 5 H), 2.95 (t, J = 8.3, 2 H), 2.67 (s, 1 H), 2.48 (s, 1 H), 2.46–2.40 (m, 1 H), 2.33–2.26 (m, 2 H), 2.21–2.17 (m, 2 H), 2.15–2.09 (m, 1 H), 1.99–1.83 (m, 4 H), 1.81–1.72 (m, 4 H), 1.69–1.64 (m, 2 H), 1.54–1.48 (m, 5 H), 1.39–1.26 (m, 15 H), 1.07 (d, J = 6.5 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 174.6, 173.8, 173.1, 172.1, 138.1, 128.9, 128.6, 126.9, 73.1, 48.1, 42.8, 40.5, 39.5, 39.2, 39.0, 37.3, 36.7, 36.4, 36.3, 29.7, 29.1, 29.0, 28.8, 28.2, 28.1, 27.8, 26.4, 26.0, 25.7, 25.5, 23.5, 20.5.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{36}\text{H}_{59}\text{N}_4\text{O}_4$: 611.4531; found: 611.4531.

1-(4-Chlorophenethyl)-2-isobutyl-1,4,8,13-tetraazacyclooctadecane-3,7,14,18-tetraone (8j)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.182g (36%); 1 mmol scale; yellow oil.

^1H NMR (500 MHz, CDCl_3): δ = 7.41–7.38 (m, 1 H), 7.35 (t, J = 5.4 Hz, 1 H), 7.31–7.28 (m, 2 H), 7.12 (d, J = 8.3 Hz, 2 H), 6.11 (t, J = 6.1 Hz, 1 H), 5.10 (s, 1 H), 3.62–3.53 (m, 2 H), 3.45–3.38 (m, 3 H), 3.18–3.11 (m, 1 H), 3.11–3.02 (m, 1 H), 2.85–2.76 (m, 1 H), 2.75–2.67 (m, 1 H), 2.58–2.51 (m, 1 H), 2.49–2.42 (m, 3 H), 2.37–2.29 (m, 2 H), 2.15–2.04 (m, 2 H), 1.93–1.84 (m, 1 H), 1.71–1.64 (m, 1 H), 1.62–1.44 (m, 6 H), 0.95 (d, J = 6.7 Hz, 3 H), 0.93 (d, J = 6.5 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.7, 173.3, 172.5, 171.7, 136.2, 132.6, 130.0, 129.00, 55.3, 47.0, 38.7, 38.4, 36.8, 35.5, 34.4, 31.5, 27.8, 24.8, 24.5, 23.0, 22.2, 21.3.

HRMS (ESI): m/z [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{26}\text{H}_{40}\text{N}_4\text{O}_4\text{Cl}$: 507.2733; found: 507.2733.

8-Benzyl-9-isopropyl-8,11,18,24-tetraazaspiro[4.21]hexacosane-7,10,17,25-tetraone (8k)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.249 g (45%); 1 mmol scale; colorless oil; a mixture of rotamers is observed and the major was used.

^1H NMR (500 MHz, CDCl_3): δ = 7.53 (s, 1 H), 7.32 (t, J = 7.5 Hz, 2 H), 7.27–7.20 (m, 1 H), 7.18 (t, J = 7.4 Hz, 1 H), 7.12 (d, J = 7.7 Hz, 2 H), 7.05 (s, 1 H), 5.92 (t, J = 5.5 Hz, 1 H), 4.80 (d, J = 17.0 Hz, 1 H), 4.66 (d, J = 17.3 Hz, 1 H), 3.51–3.35 (m, 1 H), 3.29–3.22 (m, 3 H), 3.18–3.12 (m, 1 H), 2.70 (dd, J = 24.1 Hz, 13.6 Hz, 1 H), 2.49–2.41 (m, 2 H), 2.39–2.26

(m, 2 H), 2.24–2.14 (m, 2 H), 1.97 (d, J = 14.5 Hz, 1 H), 1.82–1.76 (m, 1 H), 1.74–1.68 (m, 2 H), 1.68–1.60 (m, 3 H), 1.59–1.52 (m, 7 H), 1.49–1.45 (m, 2 H), 1.45–1.39 (m, 3 H), 1.38–1.31 (m, 1 H), 1.29–1.23 (m, 1 H), 0.98 (d, J = 6.6 Hz, 3 H), 0.88 (d, J = 6.6 Hz, 2 H), 0.81 (d, J = 6.8 Hz, 1 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 175.2, 173.2, 172.1, 169.8, 137.4, 128.7, 127.7, 126.1, 66.8, 49.5, 45.4, 44.8, 40.9, 39.5, 38.9, 38.7, 38.6, 38.4, 38.2, 36.1, 28.5, 28.4, 28.1, 27.1, 26.0, 24.1, 23.9, 23.4, 19.9, 19.3.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{32}\text{H}_{51}\text{N}_4\text{O}_4$: 555.3905; found: 555.3904.

3-Benzyl-10-methyl-7-phenethyl-3,7,13,24,31-pentaazaspiro[5.26]dotriacontane-8,12,25,32-tetraone (8l)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.200 g (28%); 1 mmol scale; brown oil.

^1H NMR (500 MHz, CDCl_3): δ = 7.51 (d, J = 6.8 Hz, 2 H), 7.41–7.35 (m, 3 H), 7.31 (d, J = 7.3 Hz, 2 H), 7.27–7.21 (m, 4 H), 6.91 (s, 1 H), 6.35 (t, J = 5.6 Hz, 1 H), 6.15 (t, J = 5.7 Hz, 1 H), 3.86 (s, 2 H), 3.78–3.64 (m, 1 H), 3.60–3.53 (m, 1 H), 3.42–3.33 (m, 1 H), 3.32–3.05 (m, 10 H), 3.01–2.93 (m, 2 H), 2.87–2.79 (m, 1 H), 2.72–2.65 (m, 1 H), 2.62–2.53 (m, 1 H), 2.44–2.38 (m, 2 H), 2.31–2.21 (m, 2 H), 2.20–2.10 (m, 2 H), 1.66–1.57 (m, 2 H), 1.53–1.42 (m, 6 H), 1.36–1.24 (m, 14 H), 1.02 (d, J = 6.3 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.8, 173.6, 173.2, 172.2, 138.0, 130.4, 128.8, 128.8, 127.9, 126.8, 61.9, 61.5, 50.2, 49.5, 46.5, 42.4, 40.7, 39.3, 39.1, 38.9, 37.1, 36.5, 31.3, 30.9, 29.0, 28.9, 28.7, 28.3, 27.9, 27.8, 27.5, 27.4, 26.5, 26.4, 26.3, 25.8, 25.5, 20.4.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{43}\text{H}_{66}\text{N}_5\text{O}_4$: 716.5109; found: 716.5114.

6-(4-Chlorophenethyl)-7-[2-(methylsulfanyl)ethyl]–6,7,9,10,11,12,13,14,16,17,18,19-dodecahydrodibenzo[*f,h*][1,4,11,14]tetraazacycloicosine-5,8,15,20-tetraone (8m)

Prepared according to procedure E and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.123 g (19%); 1 mmol scale; brown oil; a mixture of rotamers is observed and the major was used.

^1H NMR (500 MHz, CDCl_3): δ = 8.02 (s, 1 H), 7.71 (dd, J = 7.7, 1.4 Hz, 1 H), 7.52–7.46 (m, 2 H), 7.42 (dd, J = 7.6, 1.4 Hz, 2 H), 7.35 (dd, J = 7.7, 1.3 Hz, 1 H), 7.33–7.30 (m, 2 H), 7.09–7.07 (m, 2 H), 7.02–6.99 (m, 1 H), 6.86–6.75 (m, 1 H), 5.00 (s, 1 H), 4.20 (d, J = 8.4 Hz, 1 H), 3.88–3.79 (m, 1 H), 3.67–3.57 (m, 2 H), 3.47 (dd, J = 12.6, 6.5 Hz, 2 H), 3.14–3.04 (m, 3 H), 2.95–2.85 (m, 2 H), 2.28–2.19 (m, 3 H), 2.15–2.10 (m, 3 H), 2.05 (s, 3 H),

1.89–1.80 (m, 1 H), 1.74–1.66 (m, 1 H), 1.60–1.54 (m, 2 H), 1.50–1.44 (m, 1 H), 1.19–1.08 (m, 2 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.3, 172.9, 170.0, 169.1, 139.1, 137.3, 136.3, 135.8, 135.2, 133.0, 130.9, 130.5, 130.2, 129.8, 129.3, 129.0, 128.8, 128.5, 128.2, 127.8, 127.7, 124.6, 62.7, 54.0, 39.7, 39.3, 38.6, 36.9, 34.3, 30.4, 27.8, 25.6, 25.1, 24.6, 15.1.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{35}\text{H}_{42}\text{N}_4\text{O}_4\text{ClS}$: 649.2610; found: 649.2613.

25-Methyl-1-oxa-4,11,22-triazacycloheptacosane-3,10,23,27-tetraone (9a)

Prepared according to procedure F and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.181 g (40%); 1 mmol scale; white solid; mp 143–145 °C.

^1H NMR (500 MHz, CDCl_3): δ = 7.47 (t, J = 5.4 Hz, 1 H), 6.44 (t, J = 5.6 Hz, 1 H), 5.89 (t, J = 5.8 Hz, 1 H), 4.66 (d, J = 15.2 Hz, 1 H), 4.56 (d, J = 15.2 Hz, 1 H), 3.37–3.17 (m, 6 H), 2.57–2.46 (m, 1 H), 2.46–2.41 (m, 2 H), 2.31–2.24 (m, 1 H), 2.24–2.17 (m, 3 H), 1.72–1.63 (m, 2 H), 1.64–1.55 (m, 2 H), 1.55–1.45 (m, 4 H), 1.41–1.34 (m, 2 H), 1.34–1.24 (m, 12 H), 1.11 (d, J = 6.8 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.1, 171.9, 171.5, 167.6, 62.5, 42.6, 40.3, 39.4, 39.0, 38.9, 36.7, 29.3, 29.1, 28.8, 28.6, 28.5, 28.4, 28.3, 28.2, 26.4, 26.2, 25.8, 25.3, 20.9.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{24}\text{H}_{44}\text{N}_3\text{O}_5$: 454.3275; found: 454.3274.

20-Isobutyl-1-oxa-4-thia-7,13,18-triazacycloicosane-2,6,14,19-tetraone (9b)

Prepared according to procedure F and purified by column chromatography (silica gel, CH_2Cl_2 –MeOH, 9:1).

Yield: 0.103 g (25%); 1 mmol scale; white solid; mp 133–135 °C.

^1H NMR (500 MHz, CDCl_3): δ = 7.35 (d, J = 5.9 Hz, 1 H), 6.90 (s, 1 H), 6.25 (s, 1 H), 5.20 (dd, J = 9.2, 3.9 Hz, 1 H), 3.49 (s, 1 H), 3.44 (s, 1 H), 3.39 (d, J = 2.2 Hz, 2 H), 3.37–3.29 (m, 4 H), 3.26–3.21 (m, 1 H), 2.29 (t, J = 6.5 Hz, 2 H), 1.91–1.84 (m, 3 H), 1.81–1.74 (m, 3 H), 1.64–1.55 (m, 4 H), 1.45–1.39 (m, 2 H), 0.98 (d, J = 5.9 Hz, 3 H), 0.96 (d, J = 2.1 Hz, 3 H).

^{13}C NMR (126 MHz, CDCl_3): δ = 173.3, 170.5, 169.1, 168.7, 73.9, 40.9, 39.0, 38.9, 38.8, 35.9, 33.9, 33.5, 28.2, 28.2, 25.0, 24.6, 23.2, 23.1, 21.6.

HRMS (ESI): m/z $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{34}\text{N}_3\text{O}_5\text{S}$: 416.2214; found: 416.2212.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding Information

The work was financially supported by NIH 2R01GM097082-05, the Innovative Medicines Initiative (grant agreement No.115489), the European Union's Seventh Framework Programme (FP7/2007–2013), EFPIA companies' in-kind contribution, the European Union's Horizon 2020 Research and Innovation Programme under MSC ITN 'Accelerated Early Stage Drug Discovery' (No 675555), and CoFund ALERT (No 665250). E.M.M.A. was supported by the Egyptian government.

References

- (1). Villar EA; Beglov D; Chennamadhavuni S; Porco JA Jr.; Kozakov D; Vajda S; Whitty A Nat. Chem. Biol 2014, 10, 723. [PubMed: 25038790]
- (2). Heinis C Nat. Chem. Biol 2014, 10, 696. [PubMed: 25038789]
- (3). Yudin AK Chem. Sci 2015, 6, 30. [PubMed: 28553456]
- (4). De Vries J; Kellogg RM J. Am. Chem. Soc 1979, 101, 2759.
- (5). Wagler TR; Fang Y; Burrows CJ J. Org. Chem 1989, 54, 1584.
- (6). van Esch J; Kellogg RM; Feringa BL Tetrahedron Lett 1997, 38, 281.
- (7). Becerril J; Burguete MI; Escuder B; Luis SV; Miravet JF; Querol M Chem. Commun 2002, 738.
- (8). Becerril J; Burguete MI; Escuder B; Galindo F; Gavara R; Miravet JF; Luis SV; Peris G Chem. Eur. J 2004, 10, 3879. [PubMed: 15316991]
- (9). Kataoka H; Katagi T Tetrahedron 1987, 43, 4519.
- (10). Govender T; Hariprakash HK; Kruger HG; Marchand AP Tetrahedron: Asymmetry 2003, 14, 1553.
- (11). Marsault E; Peterson ML J. Med. Chem 2011, 54, 1961. [PubMed: 21381769]
- (12). Driggers EM; Hale SP; Lee J; Terrett NK Nat. Rev. Drug Discovery 2008, 7, 608. [PubMed: 18591981]
- (13). Smith JM; Frost JR; Fasan R J. Org. Chem 2013, 78, 3525. [PubMed: 23517465]
- (14). White CJ; Yudin AK Nat. Chem 2011, 3, 509. [PubMed: 21697871]
- (15). Connors WH; Hale SP; Terrett NK Curr. Opin. Chem. Biol 2015, 26, 42. [PubMed: 25710630]
- (16). Abdelraheem EMM; Kurpiewska K; Kalinowska-Thucik J; Dömling A J. Org. Chem 2016, 81, 8789. [PubMed: 27598302]
- (17). Koopmanschap G; Ruijter E; Orru RVA Beilstein J. Org. Chem 2014, 10, 544. [PubMed: 24605172]
- (18). Masson G; Neuville L; Bughin C; Fayol A; Zhu J Top. Heterocycl. Chem 2010, 25, 1. [PubMed: 20871791]
- (19). Wessjohann L; Ruijter E Mol. Diversity 2005, 9, 159.
- (20). Beck B; Larbig G; Mejat B; Magnin-Lachaux M; Picard A; Herdtweck E; Dömling A Org. Lett 2003, 5, 1047. [PubMed: 12659570]
- (21). Ugi I; Heck S Comb. Chem. High Throughput Screening 2001, 4, 1.
- (22). Cristau P; Vors JP; Zhu JP Org. Lett 2001, 3, 4079. [PubMed: 11735589]
- (23). White CJ; Yudin AK Org. Lett 2012, 14, 2898. [PubMed: 22612626]
- (24). Morejon MC; Laub A; Westermann B; Rivera DG; Wessjohann LA Org. Lett 2016, 18, 4096. [PubMed: 27505031]
- (25). Dömling A Chem. Rev 2006, 106, 17. [PubMed: 16402771]
- (26). Dömling A; Wang W; Wang K Chem. Rev 2012, 112, 3083. [PubMed: 22435608]
- (27). Vishwanatha TM; Bergamaschi E; Dömling A Org. Lett 2017, 19, 3195. [PubMed: 28581763]
- (28). Liao GP; Abdelraheem EMM; Neochoritis CG; Kurpiewska K; Kalinowska-Thucik J; McGowan DC; Dömling A Org. Lett 2015, 17, 4980. [PubMed: 26439710]

- (29). White TR; Renzelman CM; Rand AC; Rezai T; McEwen CM; Gelev VM; Turner RA; Linington RG; Leung SSF; Kalgutkar AS; Bauman JN; Zhang YZ; Liras S; Price DA; Mathiowetz AM; Jacobson MP; Lokey RS Nat. Chem. Biol 2011, 7, 810. [PubMed: 21946276]
- (30). Dömling A; Madhavachary R; Abdelraheem EMM; Rossetti A; Twarda-Clapa A; Musielak B; Kurpiewska K; Kalinowska-Tłucik J; Holak TA Angew. Chem. Int. Ed 2017, 56, 10725.

Rivera /
Wessjohann (2016)

Yudin (2012)

Dömling (2017)

Zhu (2001)

Current work

Figure 1.
Some previous and the current macrocyclic scaffolds accessible by MCR chemistry

Scheme 1.
Synthetic macrocycle pathway

Scheme 3.

Ugi-4CR-derived macrocycle synthesis; macrocyclization examples (yields of products after purification)

Scheme 4.

Passerini-3CR-derived macrocycle synthesis; macrocyclization examples (yields of products after purification)

Scheme 5.

Possible mechanism for the formation of the macrocycle by the Ugi reaction

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Structures and Yields of Amino Acid, Ester, and Coupling Products

Entry	Amino acid product 4	Ester product 5	Coupling product 6	Yield (%) ^a
1	4a	5a	6a	75
2	4b	5b	6b	40
3	4c	5c	6c	63
4	4d	5d	6d	78
5	4e	5e	6e	55
6	4f	5f	6f	88
7	4g	5g	6g	71
8	4h	5h	6h	62
9	4i	5i	6i	56
10	4j	5j	6j	50

isolated yield.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript